A case of adult type galactosialidosis with involvement of peripheral nerves

Mochizuki, Akihiko; Motoyoshi, Yasufumi; Takeuchi, Megumi; Sonoo, Masahiro; Shimizu, Teruo

doi:10.1007/s004150070116

Cited by 5 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for the dual designation is that their age of onset and clinical course vary greatly and patients present with a broad and continuous spectrum of severity of their symptoms 8,13–15 . They are mostly of Japanese origin.…”

Section: Gs: Clinical Phenotypesmentioning

confidence: 99%

Galactosialidosis: historic aspects and overview of investigated and emerging treatment options

Annunziata

d’Azzo

2016

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Introduction Galactosialidosis is a glycoprotein storage disease caused by mutations in the CTSA gene, encoding lysosomal protective protein/cathepsin A (PPCA). The enzyme’s catalytic activity is distinct from its protective function towards β-galactosidase (β-GAL) and neuraminidase 1 (NEU1), with which PPCA forms a complex. In this configuration the two glycosidases acquire their full activity and stability in lysosomes. Deficiency of PPCA results in combined NEU1/β-GAL deficiency. Because of its low incidence, galactosialidosis is considered an orphan disorder with no therapy yet available. Areas covered This review gives a historic overview on the discovery of PPCA, which defined galactosialidosis as a new clinical entity; the evidence for the existence of the PPCA/NEU1/β-GAL complex; the clinical forms of galactosialidosis and disease-causing CTSA mutations. Ppca−/− mice have proven to be a suitable model to test different therapeutic approaches, paving the way for the development of clinical trials for patients with galactosialidosis. Expert opinion Improved understanding of the molecular bases of disease has sparked renewed incentive from clinicians and scientists alike to develop therapies for rare conditions, like GS, and has increased the willingness of biotech companies to invest in the manufacturing of new therapeutics. Both ERT and gene therapy may become available to patients in the near future.

show abstract

Section: Gs: Clinical Phenotypesmentioning

confidence: 99%